Skip to main content
. 2022 Dec 1;2022:6195004. doi: 10.1155/2022/6195004

Figure 2.

Figure 2

CCL23 serum levels and baseline characteristics. Baseline CCL23 levels are unaltered between BTC patients of different tumor localization (a), T-stage (b), M-stage (d), tumor grading (e), or resection status (f). (c) BTC patients with nodal positive disease (N1) have significantly lower CCL23 levels. CCL23 levels are unaltered between male and female patients (g) as well as patients with different ECOG performance status (h).